Dystonias: Clinical Recognition and the Role of Additional Diagnostic Testing

Abstract

Dystonia is the third most common movement disorder, characterized by abnormal, frequently twisting postures related to co-contraction of agonist and antagonist muscles. Diagnosis is challenging. We provide a comprehensive appraisal of the epidemiology and an approach to the phenomenology and classification of dystonia, based on the clinical characteristics and underlying etiology of dystonia syndromes. We discuss the features of common idiopathic and genetic forms of dystonia, diagnostic challenges, and dystonia mimics. Appropriate workup is based on the age of symptom onset, rate of progression, whether dystonia is isolated or combined with another movement disorder or complex neurological and other organ system features. Based on these features, we discuss when imaging and genetic should be considered. We discuss the multidisciplinary treatment of dystonia, including rehabilitation and treatment principles according to the etiology, including when pathogenesis-direct treatment is available, oral pharmacological therapy, chemodenervation with botulinum toxin injections, deep brain stimulation and other surgical therapies, and future directions.

Keywords

dystonia - diagnosis - multidisciplinary treatment

Publikationsverlauf

Artikel online veröffentlicht:
27. März 2023

• References

• 1 Stephen CD. The dystonias. Continuum (Minneap Minn) 2022; 28 (05) 1435-1475
• 2 Klein C, Münchau A. Progressive dystonia. Handb Clin Neurol 2013; 113: 1889-1897
• 3 Lalli S, Albanese A. The diagnostic challenge of primary dystonia: evidence from misdiagnosis. Mov Disord 2010; 25 (11) 1619-1626
• 4 Marras C, Lang A, van de Warrenburg BP. et al. Nomenclature of genetic movement disorders: recommendations of the international Parkinson and movement disorder society task force. Mov Disord 2016; 31 (04) 436-457
• 5 Frucht L, Perez DL, Callahan J. et al. Functional dystonia: differentiation from primary dystonia and multidisciplinary treatments. Front Neurol 2021; 11: 605262
• 6 Berlot R, Bhatia KP, Kojović M. Pseudodystonia: a new perspective on an old phenomenon. Parkinsonism Relat Disord 2019; 62: 44-50
• 7 Steeves TD, Day L, Dykeman J, Jette N, Pringsheim T. The prevalence of primary dystonia: a systematic review and meta-analysis. Mov Disord 2012; 27 (14) 1789-1796
• 8 Cossu G, Mereu A, Deriu M. et al. Prevalence of primary blepharospasm in Sardinia, Italy: a service-based survey. Mov Disord 2006; 21 (11) 2005-2008
• 9 Sugawara M, Watanabe S, Toyoshima I. Prevalence of dystonia in Akita Prefecture in Northern Japan. Mov Disord 2006; 21 (07) 1047-1049
• 10 Fukuda H, Kusumi M, Nakashima K. Epidemiology of primary focal dystonias in the western area of Tottori prefecture in Japan: comparison with prevalence evaluated in 1993. Mov Disord 2006; 21 (09) 1503-1506
• 11 Defazio G, Abbruzzese G, Livrea P, Berardelli A. Epidemiology of primary dystonia. Lancet Neurol 2004; 3 (11) 673-678
• 12 Das SK, Banerjee TK, Biswas A. et al. Community survey of primary dystonia in the city of Kolkata, India. Mov Disord 2007; 22 (14) 2031-2036
• 13 Albanese A, Bhatia K, Bressman SB. et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord 2013; 28 (07) 863-873
• 14 Lange LM, Gonzalez-Latapi P, Rajalingam R. et al; On Behalf of the Task Force on Genetic Nomenclature in Movement Disorders. Nomenclature of genetic movement disorders: recommendations of the International Parkinson and Movement Disorder Society Task Force - an update. Mov Disord 2022; 37 (05) 905-935
• 15 Defazio G. The epidemiology of primary dystonia: current evidence and perspectives. Eur J Neurol 2010; 17 (Suppl. 01) 9-14
• 16 O'Riordan S, Raymond D, Lynch T. et al. Age at onset as a factor in determining the phenotype of primary torsion dystonia. Neurology 2004; 63 (08) 1423-1426
• 17 Asgeirsson H, Jakobsson F, Hjaltason H, Jonsdottir H, Sveinbjornsdottir S. Prevalence study of primary dystonia in Iceland. Mov Disord 2006; 21 (03) 293-298
• 18 Soland VL, Bhatia KP, Marsden CD. Sex prevalence of focal dystonias. J Neurol Neurosurg Psychiatry 1996; 60 (02) 204-205
• 19 Supnet ML, Acuna P, Carr SJ. et al. Isolated cervical dystonia: management and barriers to care. Front Neurol 2020; 11: 591418
• 20 Williams L, McGovern E, Kimmich O. et al. Epidemiological, clinical and genetic aspects of adult onset isolated focal dystonia in Ireland. Eur J Neurol 2017; 24 (01) 73-81
• 21 Brown EG, Bledsoe IO, Luthra NS, Miocinovic S, Starr PA, Ostrem JL. Cerebellar deep brain stimulation for acquired hemidystonia. Mov Disord Clin Pract (Hoboken) 2020; 7 (02) 188-193
• 22 Albanese A, Barnes MP, Bhatia KP. et al. A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur J Neurol 2006; 13 (05) 433-444
• 23 Segawa M. Dopa-responsive dystonia. Handb Clin Neurol 2011; 100: 539-557
• 24 Erro R, Sheerin UM, Bhatia KP. Paroxysmal dyskinesias revisited: a review of 500 genetically proven cases and a new classification. Mov Disord 2014; 29 (09) 1108-1116
• 25 Bruno MK, Hallett M, Gwinn-Hardy K. et al. Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: new diagnostic criteria. Neurology 2004; 63 (12) 2280-2287
• 26 Park J, Damrauer SM, Baras A, Reid JG, Overton JD, Gonzalez-Alegre P. Epidemiology of DYT1 dystonia: estimating prevalence via genetic ascertainment. Neurol Genet 2019; 5 (05) e358
• 27 Balint B, Mencacci NE, Valente EM. et al. Dystonia. Nat Rev Dis Primers 2018; 4 (01) 25
• 28 Mainka T, Erro R, Rothwell J, Kühn AA, Bhatia KP, Ganos C. Remission in dystonia - systematic review of the literature and meta-analysis. Parkinsonism Relat Disord 2019; 66: 9-15
• 29 Weissbach A, Saranza G, Domingo A. Combined dystonias: clinical and genetic updates. J Neural Transm (Vienna) 2021; 128 (04) 417-429
• 30 Patel N, Hanfelt J, Marsh L, Jankovic J. Members of the Dystonia Coalition. Alleviating manoeuvres (sensory tricks) in cervical dystonia. J Neurol Neurosurg Psychiatry 2014; 85 (08) 882-884
• 31 Filipović SR, Jahanshahi M, Viswanathan R, Heywood P, Rogers D, Bhatia KP. Clinical features of the geste antagoniste in cervical dystonia. Adv Neurol 2004; 94: 191-201
• 32 Novaretti N, Cunha ALN, Bezerra TC. et al. The prevalence and correlation of non-motor symptoms in adult patients with idiopathic focal or segmental dystonia. Tremor Other Hyperkinet Mov (N Y) 2019; 9: 596
• 33 Tinazzi M, Erro R, Mascia MM. et al. Demographic and clinical determinants of neck pain in idiopathic cervical dystonia. J Neural Transm (Vienna) 2020; 127 (10) 1435-1439
• 34 LeDoux MS, Vemula SR, Xiao J. et al. Clinical and genetic features of cervical dystonia in a large multicenter cohort. Neurol Genet 2016; 2 (03) e69
• 35 Tolosa E, Kulisevsky J, Fahn S. Meige syndrome: primary and secondary forms. Adv Neurol 1988; 50: 509-515
• 36 Tolosa E, Martí MJ. Blepharospasm-oromandibular dystonia syndrome (Meige's syndrome): clinical aspects. Adv Neurol 1988; 49: 73-84
• 37 Defazio G, Albanese A, Pellicciari R. et al. Expert recommendations for diagnosing cervical, oromandibular, and limb dystonia. Neurol Sci 2019; 40 (01) 89-95
• 38 Hassell TJW, Charles D. Treatment of blepharospasm and oromandibular dystonia with botulinum toxins. Toxins (Basel) 2020; 12 (04) 269
• 39 Britton D, Alty JE, Mannion CJ. Oromandibular dystonia: a diagnosis not to miss. Br J Oral Maxillofac Surg 2020; 58 (05) 520-524
• 40 Lo SE, Gelb M, Frucht SJ. Geste antagonistes in idiopathic lower cranial dystonia. Mov Disord 2007; 22 (07) 1012-1017
• 41 Tan EK, Jankovic J. Tardive and idiopathic oromandibular dystonia: a clinical comparison. J Neurol Neurosurg Psychiatry 2000; 68 (02) 186-190
• 42 Papapetropoulos S, Singer C. Primary focal lingual dystonia. Mov Disord 2006; 21 (03) 429-430
• 43 Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope 1998; 108 (10) 1435-1441
• 44 Frucht SJ. Embouchure dystonia: a video guide to diagnosis and evaluation. J Clin Mov Disord 2016; 3: 10
• 45 Conti AM, Pullman S, Frucht SJ. The hand that has forgotten its cunning – lessons from musicians' hand dystonia. Mov Disord 2008; 23 (10) 1398-1406
• 46 Charness ME, Ross MH, Shefner JM. Ulnar neuropathy and dystonic flexion of the fourth and fifth digits: clinical correlation in musicians. Muscle Nerve 1996; 19 (04) 431-437
• 47 Lenka A, Jankovic J. Sports-related dystonia. Tremor Other Hyperkinet Mov (N Y) 2021; 11: 54
• 48 Artusi CA, Dwivedi A, Romagnolo A. et al. Differential response to pallidal deep brain stimulation among monogenic dystonias: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2020; 91 (04) 426-433
• 49 Ozelius LJ, Hewett JW, Page CE. et al. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet 1997; 17 (01) 40-48
• 50 Saunders-Pullman R, Fuchs T, San Luciano M. et al. Heterogeneity in primary dystonia: lessons from THAP1, GNAL, and TOR1A in Amish-Mennonites. Mov Disord 2014; 29 (06) 812-818
• 51 Domingo A, Yadav R, Shah S. et al. Dystonia-specific mutations in THAP1 alter transcription of genes associated with neurodevelopment and myelin. Am J Hum Genet 2021; 108 (11) 2145-2158
• 52 Houlden H, Schneider SA, Paudel R. et al. THAP1 mutations (DYT6) are an additional cause of early-onset dystonia. Neurology 2010; 74 (10) 846-850
• 53 Blanchard A, Ea V, Roubertie A. et al. DYT6 dystonia: review of the literature and creation of the UMD locus-specific database (LSDB) for mutations in the THAP1 gene. Hum Mutat 2011; 32 (11) 1213-1224
• 54 LeDoux MS, Xiao J, Rudzińska M. et al. Genotype-phenotype correlations in THAP1 dystonia: molecular foundations and description of new cases. Parkinsonism Relat Disord 2012; 18 (05) 414-425
• 55 Steel D, Zech M, Zhao C. et al; Genomics England Research Consortium. Loss-of-function variants in HOPS complex genes VPS16 and VPS41 cause early onset dystonia associated with lysosomal abnormalities. Ann Neurol 2020; 88 (05) 867-877
• 56 Park J, Reilaender A, Petry-Schmelzer JN. et al. Transcript-specific loss-of-function variants in VPS16 are enriched in patients with dystonia. Neurol Genet 2021; 8 (01) e644
• 57 Petry-Schmelzer JN, Park J, Haack TB, Visser-Vandewalle V, Barbe MT, Wunderlich G. Long-term benefit of pallidal deep brain stimulation in a patient with VPS16-associated dystonia. Neurol Res Pract 2022; 4 (01) 21
• 58 Charlesworth G, Angelova PR, Bartolomé-Robledo F. et al. Mutations in HPCA cause autosomal-recessive primary isolated dystonia. Am J Hum Genet 2015; 96 (04) 657-665
• 59 Cai X, Chen X, Wu S. et al. Homozygous mutation of VPS16 gene is responsible for an autosomal recessive adolescent-onset primary dystonia. Sci Rep 2016; 6: 25834
• 60 Masuho I, Fang M, Geng C. et al. Homozygous GNAL mutation associated with familial childhood-onset generalized dystonia. Neurol Genet 2016; 2 (03) e78
• 61 Zech M, Lam DD, Francescatto L. et al. Recessive mutations in the α3 (VI) collagen gene COL6A3 cause early-onset isolated dystonia. Am J Hum Genet 2015; 96 (06) 883-893
• 62 Balint B, Bhatia KP. Isolated and combined dystonia syndromes - an update on new genes and their phenotypes. Eur J Neurol 2015; 22 (04) 610-617
• 63 Ichinose H, Ohye T, Matsuda Y. et al. Characterization of mouse and human GTP cyclohydrolase I genes. Mutations in patients with GTP cyclohydrolase I deficiency. J Biol Chem 1995; 270 (17) 10062-10071
• 64 Furukawa Y, Lang AE, Trugman JM. et al. Gender-related penetrance and de novo GTP-cyclohydrolase I gene mutations in dopa-responsive dystonia. Neurol 1998; 50 (04) 1015-1020
• 65 Camargos S, Scholz S, Simón-Sánchez J. et al. DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA. Lancet Neurol 2008; 7 (03) 207-215
• 66 Dos Santos CO, da Silva-Júnior FP, Puga RD. et al. The prevalence of PRKRA mutations in idiopathic dystonia. Parkinsonism Relat Disord 2018; 48: 93-96
• 67 de Gusmao CM, Stone S, Waugh JL, Yang E, Lenk GM, Rodan LH. VAC14 gene-related parkinsonism-dystonia with response to deep brain stimulation. Mov Disord Clin Pract (Hoboken) 2019; 6 (06) 494-497
• 68 Aneichyk T, Hendriks WT, Yadav R. et al. Dissecting the causal mechanism of X-linked dystonia-parkinsonism by integrating genome and transcriptome assembly. Cell 2018; 172 (05) 897-909.e21
• 69 Lee LV, Rivera C, Teleg RA. et al. The unique phenomenology of sex-linked dystonia parkinsonism (XDP, DYT3, “Lubag”). Int J Neurosci 2011; 121 (Suppl. 01) 3-11
• 70 Stephen CD, Go CL, Acuna P, Sharma N. Phasic knee bending dystonic and parkinsonian gait: a characteristic finding in X-linked dystonia parkinsonism. Mov Disord Clin Pract (Hoboken) 2020; 7 (04) 448-452
• 71 Domingo A, Lee LV, Brüggemann N. et al. Woman with X-linked recessive dystonia-parkinsonism: clue to the epidemiology of parkinsonism in Filipino women?. JAMA Neurol 2014; 71 (09) 1177-1180
• 72 Brashear A, Sweadner KJ, Cook JF, Swoboda KJ, Ozelius L. ATP1A3-related neurologic disorders. In: Adam MP, Ardinger HH, Pagon RA. et al, eds. GeneReviews(®). University of Washington; Seattle, WA: 1993-2020
• 73 Brashear A, Dobyns WB, de Carvalho Aguiar P. et al. The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene. Brain 2007; 130 (Pt 3): 828-835
• 74 Carecchio M, Invernizzi F, Gonzàlez-Latapi P. et al. Frequency and phenotypic spectrum of KMT2B dystonia in childhood: a single-center cohort study. Mov Disord 2019; 34 (10) 1516-1527
• 75 Meyer E, Carss KJ, Rankin J. et al; UK10K Consortium, Deciphering Developmental Disorders Study, NIHR BioResource Rare Diseases Consortium. Mutations in the histone methyltransferase gene KMT2B cause complex early-onset dystonia. Nat Genet 2017; 49 (02) 223-237
• 76 Kawarai T, Miyamoto R, Nakagawa E. et al. Phenotype variability and allelic heterogeneity in KMT2B-Associated disease. Parkinsonism Relat Disord 2018; 52: 55-61
• 77 Cif L, Demailly D, Lin JP. et al; Deciphering Developmental Disorders Study, Genomics England Research Consortium, NIHR BioResource, Undiagnosed Diseases Network. KMT2B-related disorders: expansion of the phenotypic spectrum and long-term efficacy of deep brain stimulation. Brain 2020; 143 (11) 3242-3261
• 78 Nardocci N. Myoclonus-dystonia syndrome. Handb Clin Neurol 2011; 100: 563-575
• 79 Zimprich A, Grabowski M, Asmus F. et al. Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. Nat Genet 2001; 29 (01) 66-69
• 80 Timmers ER, Smit M, Kuiper A. et al. Myoclonus-dystonia: distinctive motor and non-motor phenotype from other dystonia syndromes. Parkinsonism Relat Disord 2019; 69: 85-90
• 81 Zima L, Ceulemans S, Reiner G. et al. Paroxysmal motor disorders: expanding phenotypes lead to coalescing genotypes. Ann Clin Transl Neurol 2018; 5 (08) 996-1010
• 82 Leen WG, Wevers RA, Kamsteeg E-J, Scheffer H, Verbeek MM, Willemsen MA. Cerebrospinal fluid analysis in the workup of GLUT1 deficiency syndrome: a systematic review. JAMA Neurol 2013; 70 (11) 1440-1444
• 83 Yang H, Wang D, Engelstad K. et al. Glut1 deficiency syndrome and erythrocyte glucose uptake assay. Ann Neurol 2011; 70 (06) 996-1005
• 84 Latorre A, Bhatia KP. Treatment of paroxysmal dyskinesia. Neurol Clin 2020; 38 (02) 433-447
• 85 Gardiner AR, Jaffer F, Dale RC. et al. The clinical and genetic heterogeneity of paroxysmal dyskinesias. Brain 2015; 138 (Pt 12): 3567-3580
• 86 Erro R. Familial paroxysmal nonkinesigenic dyskinesia. In: Adam MP, Ardinger HH, Pagon RA. et al, eds. GeneReviews(®). University of Washington: Seattle, WA; 2019
• 87 Shetty AS, Bhatia KP, Lang AE. Dystonia and Parkinson's disease: What is the relationship?. Neurobiol Dis 2019; 132: 104462
• 88 Schneider SA, Edwards MJ, Mir P. et al. Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord 2007; 22 (15) 2210-2215
• 89 Elble RJ. Diagnostic criteria for essential tremor and differential diagnosis. Neurology 2000; 54 (11, Suppl 4): S2-S6
• 90 Obeso JA, Rothwell JC, Lang AE, Marsden CD. Myoclonic dystonia. Neurology 1983; 33 (07) 825-830
• 91 Baizabal-Carvallo JF, Alonso-Juarez M, Jankovic J. Dystonic motor and phonic tics in Tourette syndrome. J Neurol 2022; 269 (10) 5312-5318
• 92 Jinnah HA, Albanese A, Bhatia KP. et al; International Parkinson's Disease Movement Disorders Society Task Force on Rare Movement Disorders. Treatable inherited rare movement disorders. Mov Disord 2018; 33 (01) 21-35
• 93 Maas RPPWM, Wassenberg T, Lin JP, van de Warrenburg BPC, Willemsen MAAP. L-dopa in dystonia: a modern perspective. Neurology 2017; 88 (19) 1865-1871
• 94 Prudente CN, Zetterberg L, Bring A, Bradnam L, Kimberley TJ. Systematic review of rehabilitation in focal dystonias: classification and recommendations. Mov Disord Clin Pract (Hoboken) 2018; 5 (03) 237-245
• 95 Hautekiet A, Raes K, Geers S, Santens P, Oostra K. Evidence of rehabilitation therapy in task-specific focal dystonia: a systematic review. Eur J Phys Rehabil Med 2021; 57 (00) 710-719
• 96 De Pauw J, Van der Velden K, Meirte J. et al. The effectiveness of physiotherapy for cervical dystonia: a systematic literature review. J Neurol 2014; 261 (10) 1857-1865
• 97 Ramella M, Borgnis F, Giacobbi G. et al. Modified graded motor imagery for musicians' focal dystonia: a case series. Med Probl Perform Art 2021; 36 (01) 10-17
• 98 Byl NN, Nagajaran S, McKenzie AL. Effect of sensory discrimination training on structure and function in patients with focal hand dystonia: a case series. Arch Phys Med Rehabil 2003; 84 (10) 1505-1514
• 99 McCabe C. Mirror visual feedback therapy. A practical approach. J Hand Ther 2011; 24 (02) 170-178 , quiz 179
• 100 Baur B, Fürholzer W, Marquardt C, Hermsdörfer J. Auditory grip force feedback in the treatment of Writer's cramp. J Hand Ther 2009; 22 (02) 163-170 , quiz 171
• 101 Barkmeier-Kraemer JM, Clark HM. Speech-language pathology evaluation and management of hyperkinetic disorders affecting speech and swallowing function. Tremor Other Hyperkinet Mov (N Y) 2017; 7: 489
• 102 Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987; 37 (04) 616-623
• 103 Nastasi L, Mostile G, Nicoletti A, Zappia M, Reggio E, Catania S. Effect of botulinum toxin treatment on quality of life in patients with isolated lingual dystonia and oromandibular dystonia affecting the tongue. J Neurol 2016; 263 (09) 1702-1708
• 104 Dadgardoust PD, Rosales RL, Asuncion RM, Dressler D. Botulinum neurotoxin a therapy efficacy and safety for oromandibular dystonia: a meta-analysis. J Neural Transm (Vienna) 2019; 126 (02) 141-148
• 105 Rosales RL, Ng AR, Santos MM, Fernandez HH. The broadening application of chemodenervation in X-linked dystonia-parkinsonism (Part II): an open-label experience with botulinum toxin-A (Dysport®) injections for oromandibular, lingual, and truncal-axial dystonias. Int J Neurosci 2011; 121 (Suppl. 01) 44-56
• 106 Rosales RL, Santos MM, Ng AR. et al. The broadening application of chemodenervation in X-linked dystonia-parkinsonism (Part I): muscle afferent block versus botulinum toxin-A in cervical and limb dystonias. Int J Neurosci 2011; 121 (Suppl. 01) 35-43
• 107 Jankovic J. Botulinum toxin: state of the art. Mov Disord 2017; 32 (08) 1131-1138
• 108 Poliziani M, Koch M, Liu X. Striving for more good days: patient perspectives on botulinum toxin for the treatment of cervical dystonia. Patient Prefer Adherence 2016; 10: 1601-1608
• 109 Catania S. How do I evaluate and inject for writer's cramp?. Mov Disord Clin Pract (Hoboken) 2018; 5 (06) 663
• 110 Jankovic J, Adler CH, Charles D. et al. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE). J Neurol Sci 2015; 349 (1-2): 84-93
• 111 Comella C, Bhatia K. An international survey of patients with cervical dystonia. J Neurol 2015; 262 (04) 837-848
• 112 Wijemanne S, Jankovic J. Dopa-responsive dystonia – clinical and genetic heterogeneity. Nat Rev Neurol 2015; 11 (07) 414-424
• 113 Bledsoe IO, Viser AC, San Luciano M. Treatment of dystonia: medications, neurotoxins, neuromodulation, and rehabilitation. Neurotherapeutics 2020; 17 (04) 1622-1644
• 114 Jankovic J. Medical treatment of dystonia. Mov Disord 2013; 28 (07) 1001-1012
• 115 Burke RE, Fahn S, Marsden CD. Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology 1986; 36 (02) 160-164
• 116 Fahn S. Systemic therapy of dystonia. Can J Neurol Sci 1987; 14 (3, Suppl): 528-532
• 117 Cloud LJ, Jinnah HA. Treatment strategies for dystonia. Expert Opin Pharmacother 2010; 11 (01) 5-15
• 118 Mahajan A, Jankovic J, Marsh L. et al; Members of the Dystonia Coalition. Cervical dystonia and substance abuse. J Neurol 2018; 265 (04) 970-975
• 119 Kirke DN, Frucht SJ, Simonyan K. Alcohol responsiveness in laryngeal dystonia: a survey study. J Neurol 2015; 262 (06) 1548-1556
• 120 Rumbach AF, Blitzer A, Frucht SJ, Simonyan K. An open-label study of sodium oxybate in spasmodic dysphonia. Laryngoscope 2017; 127 (06) 1402-1407
• 121 Frucht SJ, Riboldi GM. Alcohol-responsive hyperkinetic movement disorders - a mechanistic hypothesis. Tremor Other Hyperkinet Mov (N Y) 2020; 10: 47
• 122 Miyazaki Y, Sako W, Asanuma K, Izumi Y, Miki T, Kaji R. Efficacy of zolpidem for dystonia: a study among different subtypes. Front Neurol 2012; 3: 58
• 123 Kupsch A, Benecke R, Müller J. et al; Deep-Brain Stimulation for Dystonia Study Group. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med 2006; 355 (19) 1978-1990
• 124 Vidailhet M, Vercueil L, Houeto JL. et al; French Stimulation du Pallidum Interne dans la Dystonie (SPIDY) Study Group. Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med 2005; 352 (05) 459-467
• 125 Volkmann J, Mueller J, Deuschl G. et al; DBS Study Group for Dystonia. Pallidal neurostimulation in patients with medication-refractory cervical dystonia: a randomised, sham-controlled trial. Lancet Neurol 2014; 13 (09) 875-884
• 126 Ostrem JL, Marks Jr WJ, Volz MM, Heath SL, Starr PA. Pallidal deep brain stimulation in patients with cranial-cervical dystonia (Meige syndrome). Mov Disord 2007; 22 (13) 1885-1891
• 127 Hao Q, Wang D, OuYang J. et al. Pallidal deep brain stimulation in primary Meige syndrome: clinical outcomes and psychiatric features. J Neurol Neurosurg Psychiatry 2020; 91 (12) 1343-1348
• 128 Alterman RL, Filippidis AS. Genetic subtypes and deep brain stimulation in dystonia. Mov Disord Clin Pract (Hoboken) 2018; 5 (04) 357-360
• 129 Kumar A, Szekely A, Jabbari B. Effective treatment of paroxysmal nonkinesigenic dyskinesia with oxcarbazepine. Clin Neuropharmacol 2016; 39 (04) 201-205
• 130 Mochel F, Hainque E, Gras D. et al. Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency. J Neurol Neurosurg Psychiatry 2016; 87 (05) 550-553
• 131 Choudhury S, Baker MR, Chatterjee S, Kumar H. Botulinum toxin: an update on pharmacology and newer products in development. Toxins (Basel) 2021; 13 (01) 58
• 132 Jankovic J, Truong D, Patel AT. et al. Injectable daxibotulinumtoxinA in cervical dystonia: a phase 2 dose-escalation multicenter study. Mov Disord Clin Pract (Hoboken) 2018; 5 (03) 273-282
• 133 Slawek J, McAllister P, Paus S, Truong D, Gross TM, Roman G, Rubio PK, Vitarella D. A phase 3, open-label, multi-center trial to evaluate the long-term safety and efficacy of repeat treatments of daxibotulinumtoxinA for injection in adults with isolated cervical dystonia. Neurology 2022; 98 (18, Suppl): 2424
• 134 Caffall ZF, Wilkes BJ, Hernández-Martinez R. et al. The HIV protease inhibitor, ritonavir, corrects diverse brain phenotypes across development in mouse model of DYT-TOR1A dystonia. Sci Transl Med 2021; 13 (607) eabd3904
• 135 Spock M, Carter TR, Bollinger KA. et al. Discovery of VU6028418: a highly selective and orally bioavailable M₄ muscarinic acetylcholine receptor antagonist. ACS Med Chem Lett 2021; 12 (08) 1342-1349